Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The therapies discussed in this article are experimental and not yet approved for general clinical use. Do not stop or change your diabetes treatment based on research developments. Always consult your healthcare provider.

Stem Cell and Immunotherapy Research for Diabetes

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Stem cell-derived beta cell therapies and immunotherapy approaches are advancing through clinical trials, with some patients achieving insulin independence for the first time since diagnosis. While a broadly available cure remains years away, the progress since 2023 has been remarkable, and the research pipeline is larger and more diverse than ever.

The Challenge: Why Diabetes Is Hard to Cure

Type 1 diabetes involves two interrelated problems:

Beta cell destruction: The immune system has destroyed the insulin-producing beta cells in the pancreas.
Autoimmune memory: Even if new beta cells are introduced, the immune system may destroy them again.

A successful cure must solve both: replace the lost beta cells and prevent the immune system from attacking the replacements.

For background on how type 1 differs from type 2, see Type 1 vs Type 2 Diabetes: Key Differences.

Stem Cell-Derived Islet Therapies

The Concept

Researchers can now grow functional insulin-producing beta cells from stem cells in the laboratory. These cells are differentiated from pluripotent stem cells into pancreatic islet cells that sense glucose and produce insulin, mimicking the function of a healthy pancreas.

Key Clinical Programs

Vertex Pharmaceuticals — Zimislecel (VX-880):

The most advanced stem cell-derived islet therapy in clinical development
Delivered via infusion into the portal vein (hepatic infusion), where the cells engraft in the liver
Requires immunosuppression to prevent rejection
Results: Some patients have achieved insulin independence or significantly reduced insulin requirements
The FORWARD phase 3 trial aims to complete enrollment of approximately 50 participants through 2025, with regulatory submissions expected in 2026
Note: A companion product (VX-264), which used an encapsulation device to avoid immunosuppression, was discontinued in March 2025 after insufficient efficacy

Throne Biotechnologies — Stem Cell Educator Therapy (SCET):

A different approach: the patient’s own blood is circulated through a device containing cord blood stem cells, which modulates the immune system
Phase 2/3 trial (NCT04011020) with 50 patients expected to conclude by mid-2025
Aims to retrain the immune system rather than replace beta cells

Other Programs:

Multiple academic and biotech groups are developing stem cell-derived islets with encapsulation strategies (physical barriers that protect cells from immune attack without requiring systemic immunosuppression)
Autologous approaches (using the patient’s own cells) are also in early development, which could potentially avoid immune rejection entirely

Immunotherapy Approaches

Immune Modulation

Rather than replacing beta cells, immunotherapy aims to halt the autoimmune destruction that causes type 1 diabetes.

Teplizumab (Tzield):

Approved by the FDA in November 2022 to delay the onset of stage 3 type 1 diabetes in high-risk individuals (ages 8+)
An anti-CD3 monoclonal antibody that modifies the T cell response against beta cells
In clinical trials, teplizumab delayed clinical diabetes onset by a median of approximately 2 years
Currently the only FDA-approved therapy that modifies the disease course of type 1 diabetes

Regulatory Cell Therapy:

Emerging strategies include the adoptive transfer of regulatory T cells (Tregs), mesenchymal stem cells (MSCs), and tolerogenic dendritic cells (DCs)
These approaches aim to re-establish immune tolerance to pancreatic antigens
Most trials are in phase I–II (83.2% of the 119 trials in this space), indicating early-stage development

Timeline and Reality Check

Milestone	Estimated Timeline
Zimislecel (VX-880) regulatory submission	2026
Potential zimislecel approval (if trials succeed)	2027–2028
Encapsulated islet therapies (no immunosuppression)	3–5+ years from 2026
Fully autologous cell therapies	5–10+ years from 2026
Combination therapy (cell replacement + immune modulation)	5–7+ years from 2026
Broadly accessible cure	Uncertain

Important caveats:

Even if approved, first-generation stem cell therapies will likely require lifelong immunosuppression, which carries its own serious risks (infection, cancer)
Access will initially be limited to specialized centers
Cost is expected to be very high
Most clinical trials are small (phase I–II); large-scale efficacy and safety data are still being gathered
These therapies target type 1 diabetes; type 2 diabetes involves different mechanisms (insulin resistance, not autoimmune destruction)

What This Means for Patients Today

For people living with type 1 diabetes now:

Do not stop insulin based on research headlines. No stem cell or immunotherapy treatment is approved for general use as a diabetes cure.
Optimize current management. Closed-loop systems, CGMs, and modern insulin analogs provide excellent glucose control today. See Diabetes Technology in 2026: Closed-Loop Systems.
Consider clinical trials. If eligible, participating in clinical trials supports research advancement. Search clinicaltrials.gov for current opportunities.
Screen at-risk family members. Islet autoantibody screening for first-degree relatives of people with type 1 diabetes can identify those in presymptomatic stages, enabling enrollment in prevention trials (like teplizumab).
Stay informed through reliable sources. The ADA, JDRF, and NIH provide evidence-based updates on research progress.

For the complete management picture, see the Complete Guide to Diabetes Management in 2026.

Key Takeaways

Stem cell-derived islet therapies (led by Vertex’s zimislecel) have shown the ability to restore insulin production in some patients with type 1 diabetes, with regulatory submissions expected in 2026.
Immunotherapy, including the FDA-approved teplizumab, can delay the onset of type 1 diabetes in high-risk individuals.
A broadly available cure is still years away; first-generation therapies will likely require immunosuppression and be limited in access.
These advances apply primarily to type 1 diabetes; type 2 diabetes involves different mechanisms.
Current management with closed-loop systems, CGMs, and modern medications remains the standard of care.
Consult your healthcare provider about eligibility for clinical trials and how emerging research may apply to your situation.

Sources

American Diabetes Association. “Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin.” June 2025. diabetes.org
National Center for Biotechnology Information. “Recent Advances in Stem Cell-Based Therapies for Type 1 Diabetes.” World Journal of Stem Cells, 2025. pmc.ncbi.nlm.nih.gov
National Center for Biotechnology Information. “First-Ever Stem Cell Therapy Restores Insulin Independence in Type 1 Diabetes.” Frontiers, 2025. pmc.ncbi.nlm.nih.gov

This article is part of the MDTalks Diabetes Hub. See also AI Answers About Diabetes.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. The therapies discussed are experimental. Never change your treatment based on research news without consulting your healthcare provider.